Perception of Canadian patients with Multiple Sclerosis on the use of cannabis to better manage the symptoms of the disease (PerSPective)

Studies

Study Title: Perception of Canadian patients with Multiple Sclerosis on the use of cannabis to better manage the symptoms of the disease (PerSPective)
Rationale: Cannabis is now legal and available to all adults in Canada. Patients and clinicians have found value in adding cannabis to the arsenal of standard MS treatments to relief MS symtoms . Currently, a randomized controlled trial is being recruited to compare the two main cannabinoids, THC and CBD, and their combination, to relieve spasticity and pain in MS (CANSEP study - NCT05092191). However, some questions remain unanswered regarding the perception of patients with multiple sclerosis (PaMS) to take cannabis as a treatment,It is therefore essential to conduct this complementary study to the CANSEP randomized clinical trial.
Study Description: This study focuses on the perception of patients with multiple sclerosis regarding therapeutic cannabis and allow us to understand the potential resistance to taking medical cannabis by PwMS. To participatie in PESPECTIVE study, PwMS have to complete an online questionnaire. The duration is average 15 minutes.e
PERSPECTIVE study represents an opportunity to identify the key elements that influence the perception of PwMS regarding therapeutic cannabis and, by extension, the factors facilitating or limiting its use.

https://redcap.link/PERSPECTIVE

Recruitment Dates: 2023-01-10 to 2023-04-15
Who can participate: PwMS, aged 21 and over
Location of Trial: research center of the Montreal's university hospital center(CRCHUM)
Trial Investigator: Dr Marie-Pascale Pomey and Dr Pierre Duquette
Contact Information: Dr Pierre Duquette
pierre.duquette.med@ssss.gouv.qc.ca
Trial Funding: IRSC/MSSC